Delivery Order SPE2DB20D3103-SPE2DB23FN3V1

Award Date 5/12/23
Potential Completion Date 5/15/23
Potential Value $7.9K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,981.04, is a delivery order for the supply of Restasis 0.05% Eye Emulsion. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Restasis 0.05% eye emulsion. The contract, valued at $3,180.58, is a firm fixed-price delivery order with a completion date of November 26, 2021. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to...
This federal contract award, valued at $5,487.45, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Restasis 0.05% eye emulsion, a prescription ophthalmic medication, to support military healthcare programs. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,628.38 delivery order contract is for the supply of Restasis 0.05% eye emulsion 60s, a specialty pharmaceutical product. The award is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical valued at up to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,537.07 firm fixed-price delivery order is for the supply of Restasis 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of November 3, 2021 and was awarded on November 2, 2021. This delivery order is part of a larger $999,999,999 Indefinite...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $4,895.09 delivery order is for the supply of Restasis 0.05% eye emulsion, a prescription drug. The contract has an ultimate completion date of September 27, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and DLA Troop Support Medical, valued up to $999,999,999 through...
This federal contract award, valued at $6,319.93, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Restasis 0.05% eye emulsion, a prescription eye medication. The award was made as a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to...
This federal contract award, valued at $11,648.39, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product, with a completion date of October 21, 2024. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,046.52 firm fixed-price delivery order is for the supply of Restasis 0.05% eye emulsion, a specialty ophthalmic medication. The contract has a performance period ending on July 27, 2022 and was awarded on July 26, 2022. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,992.80 firm fixed-price delivery order is for the supply of Restasis 0.05% eye emulsion. The contract has an ultimate completion date of June 1, 2022. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical....
  • SPE2DB20D3103
    Indefinite Delivery Contract
  • SPE2DB20D3103-SPE2DB23FN3V1
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,893.39, is for the delivery of Restasis 0.05% Eye Emulsion medical product. The award is a delivery order with a firm fixed price. The contract has an ultimate completion date of May 15, 2023. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. The IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition.

Generated 5/9/25, 9:48 AM